Capricor (CAPR) | Financial Analysis & Statements
Capricor Therapeutics Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-29.2M
Net Income
-30.2M
EPS (Diluted)
$-0.62
Balance Sheet Metrics
Total Assets
355.9M
Total Liabilities
50.2M
Shareholders Equity
305.8M
Debt to Equity
0.16
Cash Flow Metrics
Operating Cash Flow
-22.4M
Free Cash Flow
-28.7M
Revenue & Profitability Trend
Capricor Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 22.3M | 25.2M | 2.6M | 244.9K |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 84.5M | 50.0M | 36.4M | 21.8M | 13.6M |
| Selling, General & Administrative | 22.7M | 14.2M | 12.4M | 10.3M | 7.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 107.2M | 64.2M | 48.8M | 32.1M | 21.2M |
| Operating Income | -108.1M | -42.6M | -24.1M | -29.7M | -20.9M |
| Operating Margin % | 0.0% | -191.1% | -95.6% | -1,163.9% | -8,549.9% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 3.0M | - | - | - | - |
| Other Non-Operating Income | 6.1M | 2.1M | 1.8M | 677.9K | 915.9K |
| Pre-tax Income | -105.0M | -40.5M | -22.3M | -29.0M | -20.0M |
| Income Tax | 1.6K | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -105.0M | -40.5M | -22.3M | -29.0M | -20.0M |
| Net Margin % | 0.0% | -181.7% | -88.5% | -1,137.4% | -8,175.9% |
| Key Metrics | |||||
| EBITDA | -106.2M | -43.2M | -24.7M | -29.7M | -21.1M |
| EPS (Basic) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| EPS (Diluted) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| Basic Shares Outstanding | 46478416 | 35218628 | 26778360 | 24552688 | 23089323 |
| Diluted Shares Outstanding | 46478416 | 35218628 | 26778360 | 24552688 | 23089323 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Capricor Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 287.8M | 11.3M | 14.7M | 9.6M | 34.9M |
| Short-term Investments | 30.3M | 140.2M | 24.8M | 31.8M | 0 |
| Accounts Receivable | 59.2K | 10.4M | 10.4M | 547.6K | 391.8K |
| Inventory | - | - | - | - | - |
| Other Current Assets | 4.8M | 1.5M | 995.8K | 919.9K | 1.2M |
| Total Current Assets | 322.9M | 163.4M | 50.9M | 42.9M | 36.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 22.3M | 7.6M | 7.5M | 6.6M | 5.3M |
| Goodwill | - | - | - | - | 0 |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.2M | 221.7K | 268.2K | 268.2K | 275.7K |
| Total Non-Current Assets | 33.0M | 7.1M | 7.9M | 7.2M | 4.9M |
| Total Assets | 355.9M | 170.5M | 58.7M | 50.1M | 41.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.7M | - | 6.2M | 4.8M | - |
| Short-term Debt | 202.4K | 834.8K | 749.1K | 682.0K | 417.6K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 6.4M | - | - | - | - |
| Total Current Liabilities | 35.8M | 21.0M | 31.3M | 23.6M | 4.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 14.3M | 616.3K | 1.5M | 1.9M | 2.5M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | 3.4M | 3.4M | 3.4M | 3.4M |
| Total Non-Current Liabilities | 14.3M | 4.0M | 4.9M | 14.7M | 5.8M |
| Total Liabilities | 50.2M | 25.0M | 36.1M | 38.3M | 10.0M |
| Equity | |||||
| Common Stock | 57.4K | 45.6K | 31.1K | 25.2K | 24.2K |
| Retained Earnings | -304.9M | -199.8M | -159.4M | -137.1M | -108.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 305.8M | 145.5M | 22.6M | 11.8M | 31.4M |
| Key Metrics | |||||
| Total Debt | 14.5M | 1.5M | 2.2M | 2.6M | 2.9M |
| Working Capital | 287.1M | 142.4M | 19.6M | 19.3M | 32.3M |
Balance Sheet Composition
Capricor Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -105.0M | -40.5M | -22.3M | -29.0M | -20.0M |
| Depreciation & Amortization | 1.9M | 1.4M | 1.1M | 533.1K | 245.7K |
| Stock-Based Compensation | 17.2M | 9.8M | 7.4M | 4.5M | 3.0M |
| Working Capital Changes | 10.3M | -12.3M | -11.7M | 28.5M | 249.7K |
| Operating Cash Flow | -71.9M | -41.6M | -25.5M | 4.6M | -16.5M |
| Investing Activities | |||||
| Capital Expenditures | -11.7M | -1.5M | -2.0M | -3.4M | -1.2M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -151.4M | -208.4M | -97.4M | -114.2M | 0 |
| Investment Sales | 260.6M | 93.8M | 104.6M | 82.5M | 0 |
| Investing Cash Flow | 97.5M | -116.2M | 5.1M | -35.1M | -1.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 237.0M | 152.3M | 25.5M | 4.8M | 20.2M |
| Free Cash Flow | -81.5M | -41.5M | -27.6M | 1.6M | -18.0M |
| Net Change in Cash | 262.7M | -5.5M | 5.1M | -25.6M | 2.5M |
Cash Flow Trend
Capricor Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-15.61
Forward P/E
-56.73
Price to Book
6.62
PEG Ratio
-0.05
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-46.56%
Return on Assets
-25.68%
Financial Health
Current Ratio
9.01
Debt to Equity
4.75
Beta
0.48
Per Share Data
EPS (TTM)
$-2.26
Book Value per Share
$5.33
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CAPR | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






